There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

The present invention provides compounds that are dual inhibitors of soluble epoxide hydrolase and fatty acid amide hydrolase. The present invention also provides methods of using the compounds to inhibit soluble epoxide hydrolase and fatty acid amide hydrolase, and to treat cancer.

The present invention provides compounds that are dual inhibitors of soluble epoxide hydrolase and fatty acid amide hydrolase. The present invention also provides methods of using the compounds to inhibit soluble epoxide hydrolase and fatty acid amide hydrolase, and to treat cancer.

There is provided a novel gelator containing a monourea derivative. A gelator comprising a compound of formula (1): ##STR00001##
wherein R.sup.1 is a linear or branched alkyl group having a carbon atom number of 2 to 20, a cyclic alkyl group having a carbon atom number of 3 to 20, or a linear or branched alkenyl group having a carbon atom number of 12 to 20; and Ar is a C.sub.6-18 aryl group unsubstituted or optionally substituted with at least one substituent selected from the group consisting of a C.sub.1-10 alkyl group, a C.sub.1-10 alkoxy group, a C.sub.6-18 aryloxy group, a halogen atom, a nitro group, a phenyl group, a C.sub.2-10 alkylcarbonyl group, and a C.sub.7-18 aralkyl group.

There is provided a novel gelator containing a monourea derivative. A gelator comprising a compound of formula (1): ##STR00001##
wherein R.sup.1 is a linear or branched alkyl group having a carbon atom number of 2 to 20, a cyclic alkyl group having a carbon atom number of 3 to 20, or a linear or branched alkenyl group having a carbon atom number of 12 to 20; and Ar is a C.sub.6-18 aryl group unsubstituted or optionally substituted with at least one substituent selected from the group consisting of a C.sub.1-10 alkyl group, a C.sub.1-10 alkoxy group, a C.sub.6-18 aryloxy group, a halogen atom, a nitro group, a phenyl group, a C.sub.2-10 alkylcarbonyl group, and a C.sub.7-18 aralkyl group.

The present application provides compounds that modulate the activity of one or more eIF2 kinases. Pharmaceutical compositions and methods of treating diseases related to one or more eIF2 kinases are also provided.

The present application provides compounds that modulate the activity of one or more eIF2 kinases. Pharmaceutical compositions and methods of treating diseases related to one or more eIF2 kinases are also provided.

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.